SCHEMBL6069353

SCHEMBL6069353

NCCNc1ccc(-c2ccccc2CO)c(-c2ccc(Cl)cc2Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G1B P04054 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
ATG4B Q9Y4P1 1/20 0.39
DPP4 P27487 2/20 0.38
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
CSNK2A1 P68400 1/20 0.38
CSNK2A3 Q8NEV1 1/20 0.38
ACKR3 P25106 2/20 0.38
HTR2B P41595 2/20 0.38
CNR1 P21554 2/20 0.38
SUV39H2 Q9H5I1 2/20 0.37
ITGA1 P56199 1/20 0.36
ADORA2A P29274 1/20 0.36
MAPT P10636 2/20 0.36
MEN1 O00255 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6069348 0.74 IDO1 (0.40) PLA2G1BCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL6647942 0.71 DPP4 (0.69) CYP3A4DPP4CSNK2A2CSNK2BCSNK2A1
SCHEMBL5100238 0.69 GSK3B (0.43) CYP1A2CYP2D6DPP4ACKR3HTR2B
SCHEMBL14686270 0.68 DPP4 (0.48) CYP3A4DPP4CSNK2A2CSNK2BCSNK2A1
SCHEMBL6068869 0.68 CYP2A13 (0.56) MAPTMEN1KMT2A
SCHEMBL30479701 0.66 TERT (0.55) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL291122 0.66 TERT (0.55) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
Anthraquinone SCHEMBL2033678 0.66 TERT (0.55) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL3863811 0.66 DPP4 (0.63) DPP4CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL2394244 0.66 CSNK2A2 (0.47) CYP2C9CYP2C19DPP4CSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6989382-B2 Carbocycle based inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION (US) 2006-01-24 US disclosed
US-20040138273-A1 Carbocycle based inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138273-A1 Carbocycle based inhibitors of glycogen synthase kinase 3 GSK3B, GSK3A, GSKIP PLA2G1B 3917/4885CYP1A2 2166/4885CYP3A4 2543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.